Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide

Journal of Surgical Research

Volumn 102, Issue 2, 2002, Pages 95-101

  Yoshida, Masanori ^a   Yamamoto, Naritaka ^a   Nitta, Takashi ^a   Uehara, Tetsuya ^a   Terao, Ryuta ^a   Hatano, Etsuro ^a   Iimuro, Yuji ^a   Yamaoka, Yoshio ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Biliary tract; Cytostatic gene therapy; E2F decoy; Hemagglutinating virus of Japan; Hepatolithiasis; Liposome; Proliferative cholangitis; Rat

Indexed keywords

ANION; BROXURIDINE; CYCLINE; CYTOSTATIC AGENT; DOUBLE STRANDED DNA; LIPOSOME; NYLON; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR E2F; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT; BILE DUCT STONE; CELL PROLIFERATION; CHOLANGITIS; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; EXPERIMENTAL MODEL; GENE THERAPY; GENETIC TRANSFECTION; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; RAT; RECURRENT DISEASE;

EID: 0036351285     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2001.6301     Document Type: Article

References (35)

1. Surgical management of intrahepatic gallstones
2. Treatment of hepatolithiasis: Improvement of result by a systematic approach
3. Hepatolithiasis in East Asia. Retrospective study
4. Pathologic features of hepatolithiasis in Japan
5. Biliary strictures as a cause of primary intrahepatic bile duct stones
6. Bile duct stents in the management of hepatolithiasis with long-segment intrahepatic biliary strictures
7. Dilatation of intrahepatic biliary strictures in patients with hepatolithiasis
8. The role of E2F in the mammalian cell cycle
9. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
10. The transcription factor E2F-1 mediates the autoregulation of RB gene expression
11. Nuclear factor E2F mediates basic transcription and trans-activation by Ela of the human MYC promoter
12. Cell cycle regulation of the human cdc2 gene
13. Activation of the mouse proliferating cell nuclear antigen gene promoter by adenovirus type 12 E1A proteins
14. E1A-dependent trans-activation of the human MYC promoter is mediated by the E2F factor
15. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
16. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides
17. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
18. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo
19. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro
20. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor
21. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates
22. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial
23. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract
24. Gene transfer to the rat biliary tract with the HVJ-cationic liposome method
25. Surgical treatment of hepatolithiasis: Long-term results
26. Choledochoscopic removal of retained stones via a T-tube tract
27. Percutaneous transhepatic removal of common bile duct and intrahepatic duct stones with a fiber-optic choledochoscope
28. Biliary stricture dilatation: Multicenter review of clinical management in 73 patients
29. Balloon dilatation of intrahepatic duct and biliary-enteric anastomosis strictures. Long term results
30. Long-term results of one hundred and seven hepatic resections for intrahepatic stones
31. Hepatic resection for hepatolithiasis and long-term results
32. Balloon dilatation of intrahepatic duct and biliary-enteric anastomosis strictures-long term result
33. Fusigenic viral liposome for gene therapy in cardiovascular diseases
34. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: Enhanced therapeutic utility for restenosis by HVJ-liposome delivery
35. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia